NCT06196515 Anti-bacterial Potential of Nano Calcium Hydroxide as an Intracanal Medication
| NCT ID | NCT06196515 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | British University In Egypt |
| Condition | Endodontic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2024-08 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 54 participants in total. It began in 2024-08 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to evaluate the anti-bacterial potential of Nano Calcium Hydroxide as an intracanal medication in primary endodontic treatment of permanent molars.
Eligibility Criteria
Inclusion Criteria: * healthy males and females. * age range between 21-49. * patients with no physical disability or psychological problems. * patients presenting with single permanent molar with signs and/or symptoms of apical periodontitis, and having Periapican index ≥ 2. Exclusion Criteria: * pregnant women. * patients with immune-compromised disease. * patients with complicated systemic diseases. * patients who took antibiotics within a period of 1 month. * patients with known sensitivity to the medicaments or pharmaceuticals used in this study. * Non-restorable teeth including root fractures, and/or advanced periodontal involvement.
Contact & Investigator
Shehab Eldin M Saber, doctoral
STUDY DIRECTOR
British University In Egypt
Frequently Asked Questions
Who can join the NCT06196515 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 49 Years, studying Endodontic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06196515 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06196515 currently recruiting?
Yes, NCT06196515 is actively recruiting participants. Contact the research team at pg.nada92140021@bue.edu.eg for enrollment information.
Where is the NCT06196515 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06196515 clinical trial?
NCT06196515 is sponsored by British University In Egypt. The principal investigator is Shehab Eldin M Saber, doctoral at British University In Egypt. The trial plans to enroll 54 participants.